证券代码：603127 证券简称：昭衍新药 公告编号：2025-029 北京昭衍新药研究中心股份有限公司 2024年年度A 股权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.03元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/13 | － | 2025/8/14 | 2025/8/14 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经北京昭衍新药研究中心股份有限公司（以下简称"公司"）2025 年 6 月 18 日的2024年年度股东大会、2025 年第二次 A 股类别股东会议及 2025 年第二次 H 股类别 股东会议审议通过。 二、 分配方案 1. 发放年度：2024年年度 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简 ...

北京市天元律师事务所 关于北京昭衍新药研究中心股份有限公司 差异化分红事项的专项法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号 国际企业大厦 A 座 509 单元 邮编：100033 1、本所仅根据本法律意见出具之日之前发生的事实、本所对该等事实的了 解及对本法律意见出具之日之前颁布施行的有关法律法规的理解发表法律意见。 致：北京昭衍新药研究中心股份有限公司 北京市天元律师事务所（以下简称"本所"）受北京昭衍新药研究中心股份 有限公司（以下简称"公司"或"上市公司"）的委托，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上海证券交易所上市公司自律监管指引第7号——回购股份》（以下简称 "《监管指引第7号》"）等相关法律、行政法规、部门规章及其他规范性文件（以 下合称"法律法规"）以及《北京昭衍新药研究中心股份有限公司章程》（以下简 称"《公司章程》"），就公司2024年度利润分配所涉及的差异化分红（以下简称"本 次差异化分红"）相关事项出具本法律意见。 为出具本法律意见之目的，本所根据相关法律法规的规定对涉及公司本次差 异化分 ...

Group 1 - The stock price of Zhaoyan New Drug as of August 4, 2025, is 31.28 yuan, down 3.04% from the previous trading day [1] - The opening price on the same day was 32.12 yuan, with a high of 32.16 yuan and a low of 30.01 yuan, resulting in a total trading volume of 1.246 billion yuan and a turnover rate of 6.41% [1] - Zhaoyan New Drug operates in the medical services sector, focusing on innovative drug research and development services, including drug safety evaluation and pharmacology efficacy research [1] Group 2 - During the early trading session on August 4, Zhaoyan New Drug experienced a rapid rebound, with a price increase of over 2% within 5 minutes [1] - By 9:40 AM, the stock price was reported at 31.28 yuan with a trading volume of 234 million yuan [1] - On August 4, the net outflow of main funds was 55.3549 million yuan, accounting for 0.28% of the circulating market value, with a cumulative net outflow of 338 million yuan over the past five trading days, representing 1.71% of the circulating market value [1]

Company Overview - Zhaoyan New Drug Research Center Co., Ltd. focuses on non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] - The main products include non-clinical research services, clinical services, and experimental model supply [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54% [1] - The net profit for the same period was 41.12 million yuan, showing a year-on-year increase of 115.11% [1] - The gross profit margin was recorded at 28.61% [1] Market Position - As of August 4, the company's stock closed at 31.28 yuan, down 3.04%, with a rolling PE ratio of 60.51 times [1] - The total market capitalization is 23.444 billion yuan [1] - In terms of industry PE ratio, the average for the medical services sector is 47.79 times, with a median of 59.03 times, placing Zhaoyan New Drug at the 30th position [1][2] Institutional Holdings - As of Q1 2025, 17 institutions hold shares in Zhaoyan New Drug, all of which are funds, with a total holding of 10.9687 million shares valued at 231 million yuan [1]

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Core Insights - The CSI 1000 Healthcare Index has shown significant growth, with a 13.89% increase over the past month, 24.30% over the last three months, and 27.10% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 13651.50 points [1] - The index is designed to provide a diversified investment option by selecting liquid and representative securities from each industry [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Borui Pharmaceutical (3.51%) - Tonghua Golden Horse (2.65%) - Zai Lab (2.51%) - Zhongsheng Pharmaceutical (1.75%) - Zhaoyan New Drug (1.70%) - Anke Biotechnology (1.66%) - Yipinhong (1.63%) - Zuoli Pharmaceutical (1.59%) - Furuide (1.39%) - Dongcheng Pharmaceutical (1.33%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.62%, while the Shenzhen Stock Exchange accounts for 44.38% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 36.28% - Medical devices: 19.30% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.30% - Medical commerce and services: 7.16% - Pharmaceutical and biotechnology services: 5.94% [2] Group 4: Sample Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments [2] - When a sample company is delisted, it will be removed from the index, and any mergers, acquisitions, or splits will be handled according to maintenance guidelines [2]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 56.33 | 8.37% | 17.94万 | | 10.12亿 | | 002173 | 创新医疗 | 15.34 | 7.72% | 76.57万 | | 11.37亿 | | 301096 | 百诚医药 | 58.45 | 7.09% | 17.58万 | | 10.01亿 | | 000710 | 贝瑞基因 | 14.64 | 4.95% | 56.75万 | | 8.30亿 | | 301293 | 三博脑科 | 50.08 | 3.58% | 14.57万 | | 7.19 Z | | 300149 | 睿智医药 | 14.24 | 3.56% | 134.38万 | | 18.69亿 | | 000504 | *ST生物 | 10.67 | 3.39% | 5.73万 | | 6098.79万 | | 300244 | 迪安诊断 | 16.10 | 1.58% | 37.94万 | | ...

数据来源：天眼查APP 证券之星消息，根据天眼查APP数据整理，近日，华夏致远创业投资基金(北京)合伙企业(有限合伙)成 立，法定代表人为华夏股权投资基金管理(北京)有限公司，注册资本3500万元，经营范围包含：一般项 目：创业投资(限投资未上市企业)；以私募基金从事股权投资、投资管理、资产管理等活动(须在中国证 券投资基金业协会完成登记备案后方可从事经营活动)。(除依法须经批准的项目外，凭营业执照依法自 主开展经营活动)(不得从事国家和本市产业政策禁止和限制类项目的经营活动。)。天眼查APP股权穿透 显示，该公司由昭衍新药、华夏股权投资基金管理(北京)有限公司、乐普(北京)医疗器械股份有限公司 共同持股。 ...

Core Viewpoint - The stock of Beijing Zhaoyan New Drug Research Center Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days in July 2025 [2][3]. Group 1: Stock Trading Abnormality - The company's stock price increased significantly on July 25, 28, and 29, 2025, with a cumulative closing price deviation exceeding 20%, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][3]. Group 2: Company Operations and Major Events - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external business environment that would affect the stock price [4]. - A self-examination and inquiry with the controlling shareholder and actual controller revealed no undisclosed major events that could impact the stock price, including significant asset restructuring or share issuance [5]. - The company did not identify any media reports or market rumors that require clarification or response, nor any other significant events that could substantially affect the stock price [6]. Group 3: Insider Trading and Board Statement - The company verified that there were no transactions involving the company's stock by the controlling shareholder, actual controller, directors, supervisors, or senior management during the period of abnormal trading fluctuation [7]. - The board of directors confirmed that there are no undisclosed matters or plans that should have been disclosed according to the relevant regulations, and previous disclosures do not require correction or supplementation [9].

证券代码：603127 证券简称：昭衍新药 公告编号：2025-028 北京昭衍新药研究中心股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、股票交易异常波动的具体情况 公司股票于 2025 年 7 月 25 日、7 月 28 日和 7 月 29 日连续 3 个交易日内日 收盘价格涨幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规 定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，现将有关情况说 明如下： （一）生产经营情况 经自查，公司目前生产经营活动正常，内、外部经营环境未发生重大变化， 不存在影响公司股票交易价格异常波动的应披露而未披露的重大信息。 （二）重大事项情况 经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，不存 在影响公司股票交易价格异常波动的重大事项，不存在涉及公司应披露而未披露 的重大信息，包括但不限于重大资产重组、发行股份、上市公司收购、债务重组、 资产 ...